SEC Company Response from Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114) (ARMP) — May 11, 2016
Armata Pharmaceuticals, Inc. (ARMP) (CIK 0000921114)
Date: May 11, 2016 · CIK: 0000921114 · Accession: 0001144204-16-100880
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-210974
Letter
AmpliPhi Biosciences Corporation
3579 Valley Centre Drive, Suite 100
San Diego, CA 92130
May 11, 2016
Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Suzanne Hayes
Dorrie Yale
Re: AmpliPhi Biosciences Corporation (the “Company”)
Registration Statement on Form S-3, as amended (File No. 333-210974)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on May 13, 2016 or as soon thereafter as is practicable.
In connection with this request, the Company acknowledges that:
· should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert Staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this request, please contact Thomas A. Coll of Cooley LLP at (858) 550-6013.
Very truly yours,
AmpliPhi
Biosciences Corporation
Show Raw Text
CORRESP
1
filename1.htm
AmpliPhi
Biosciences Corporation
3579 Valley Centre Drive, Suite 100
San Diego, CA 92130
May 11, 2016
Via
Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Suzanne Hayes
Dorrie Yale
Re: AmpliPhi Biosciences Corporation (the “Company”)
Registration Statement on Form S-3, as amended (File No. 333-210974)
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”)
take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern
Time on May 13, 2016 or as soon thereafter as is practicable.
In connection with this request, the Company
acknowledges that:
· should the Commission or the staff of the Commission (the “Staff”), acting
pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with
respect to the filing;
· the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring
the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure
in the filing; and
· the Company may not assert Staff comments and the declaration of effectiveness as a defense in
any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you have any questions regarding this
request, please contact Thomas A. Coll of Cooley LLP at (858) 550-6013.
Very truly yours,
AmpliPhi
Biosciences Corporation
By: /s/ M. Scott Salka
M. Scott Salka
Chief Executive Officer